RE: Strategy - off topic21 Aug 2021 16:53
Hi Alas,
Virolens is a ‘turnstile test’. There is no other on the market yet but others are likewise progressing holographic imaginary for detecting pathogens.
There really isn’t a sufficient moat to ‘Warren Buffet’ this business. It’s high tech, relatively low margin work. It’s usp is it’s high end tech, worldwide coverage and ability to deliver bespoke products at volume with excellent customer links. You can see all the blurb on the webpage. There are many others in this market.
It’s a great recovery play and is moving under its own steam. A Virolens announcement will supercharge the SP!
LFT’s have their place but they really would have worked better in conjunction with covid passports. The narrative around testing and passports seems to have taken a back seat to vax and booster vax and get on with it. The UK is becoming a paradigm for that model.
Even with the narrative changing things like cruise ships, airports, schools, doctors surgeries, police stations, nursing homes etc Could cope better with a rapid covid test than a cumbersome up to 15min LFT. At the moment it’s really down to the individual to decide if they take an LFT before visiting granny even if both are double jabbed.
We know Virolens has MHRA approval. We know of the Scotland trials and Heathrow. We know the financial results included numbers ‘aside from Virolens’ but other than that it’s been very quiet.
If I was looking to enter now I would be looking at the order book in the results, the outlook, the divi cover and BoD skill with acquisitions.
If you think it can stand-alone on those fundamentals then you get Virolens as a potential share price super charger event!
Without the potential of Virolens I wouldn’t have invested. Ironically now I have I have been very pleased with this companies performance especially dealing with supply side constraints.
Usual caveats
Trek